Table 1.
Clinical characteristics and QTc interval evolution in the three treatment groups.
| Group 1 (one drug) N = 9 (13.0%) |
Group 2 (two drugs) N = 37 (53.6%) |
Group 3 (three drugs) N = 23 (33.3%) |
P | |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Age [years] | 55.0 ± 18.3 | 66.0 ± 16.2 | 58.0 ± 15.8 | 0.248 |
| Male sex | 6 (66.7%) | 25 (67.6%) | 18 (78.3%) | 0.643 |
| Dyslipidemia | 5 (55.6%) | 9 (24.3%) | 7 (30.4%) | 0.749 |
| Diabetes | 7 (77.8%) | 4 (10.8%) | 5 (21.7%) | 0.525 |
| Hypertension | 3 (33.3%) | 16 (43.2%) | 8 (34.8%) | 0.387 |
| Previous cardiopathy | 6 (66.7%) | 11 (29.7%) | 3 (13.0%) | 0.305 |
| COPD | 7 (77.8%) | 6 (16.2%) | 1 (8.7%) | 0.679 |
| Atrial fibrillation | 1 (11.1%) | 3 (8.1%) | 0 | 0.297 |
| Mortality | 0 | 4 (10.8%) | 0 | 0.159 |
| QTc interval | ||||
| QTc interval at admission [ms] | 340.0 [320.0–350.0] | 408.0 [377.2–423.5] | 394.0 [373.0–422.5] | 0.039 |
| Maximal QTc interval [ms] | 418.0 [384.5–460.5] | 426.0 [412.0–450.0] | 435.0 [405.0–450.0] | 0.085 |
| QTc > 450 ms | 3 (33.3%) | 9 (24.3%) | 6 (26.1%) | 0.859 |
| ΔQTc > 60 ms | 1 (11.1%) | 4 (15.4%) | 3 (9.7%) | 0.818 |
Qualitative variables are shown as number (percentage); quantitative variables are shown as mean ± standard deviation or median [interquartile range], as appropriate; COPD — chronic obstructive pulmonary disease